科研人员发现致命脑癌的治疗薄弱点

俄亥俄州立大学的研究团队发现了针对胶质母细胞瘤的新治疗策略，通过阻断SET蛋白可能为这种最致命的脑癌患者带来希望。1在临床前研究中，该团队发现阻断SET、ANP32A和CIP2A三种蛋白不仅能防止肿瘤形成，还能显著增强癌细胞对放射线的敏感性。1

这一治疗策略的作用机制是通过恢复PP2A酶的活性。1研究人员发现SET蛋白在阻断PP2A酶活性中起关键作用，而恢复这种酶的功能可能会使胶质母细胞瘤细胞更难以存活治疗。1该团队还发现一种已获美国食品药品监督管理局批准的抗精神病药物能够增加PP2A的活性，为进一步的临床应用提供了可能。1

这项研究成果已发表于2026年5月的《癌症快报》期刊。1尽管在实验室和动物模型中显示了明显效果，这一策略仍需要进行人体试验来验证其安全性和有效性。1

Researchers at Ohio State University's Comprehensive Cancer Center have discovered a vulnerability in glioblastoma, one of the most lethal brain cancers, by identifying the SET protein as a key regulator blocking tumor suppression.1 In preclinical models, blocking the SET protein prevented tumor formation, while inhibiting SET along with related proteins ANP32A and CIP2A rendered cancer cells more sensitive to radiation therapy.1 The therapeutic strategy works by restoring activity of the PP2A enzyme, which normally acts as a tumor suppressor.1

The research team, led by Dr. Arnab Chakravarti, also identified an FDA-approved antipsychotic drug capable of increasing PP2A activity, offering a potential pharmacological approach to the treatment strategy.1 According to Dr. Chakravarti, "Restoring PP2A activity could make glioblastoma cells harder to survive treatment."1 The findings were published in Cancer Letters in May 2026.1 Human clinical trials will be necessary to establish the safety and efficacy of this approach in patients with the disease.